A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01-AR053643 to LIP and, KO2-AR02127, R03 TW006919, R01-DK076007, and P01-AG13918)
This publication has 33 references indexed in Scilit:
- Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viabilityBone, 2011
- Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts In VivoJournal of Bone and Mineral Research, 2008
- Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loadingBone, 2007
- Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogsBone, 2006
- Bisphosphonates and Estrogens Inhibit Osteocyte Apoptosis via Distinct Molecular Mechanisms Downstream of Extracellular Signal-regulated Kinase ActivationJournal of Biological Chemistry, 2005
- Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosisLife Sciences, 2004
- From Molds and Macrophages to Mevalonate: A Decade of Progress in Understanding the Molecular Mode of Action of BisphosphonatesCalcified Tissue International, 2004
- Transduction of Cell Survival Signals by Connexin-43 HemichannelsJournal of Biological Chemistry, 2002
- Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitoninJournal of Clinical Investigation, 1999
- Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivoJournal of Bone and Mineral Research, 1995